Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo

Simrit Parmar, Xiaoying Liu, Amer Najjar, Nina Shah, Hong Yang, Eric Yvon, Katy Rezvani, Ian McNiece, Patrick Zweidler-McKay, Leonard Miller, Steve Wolpe, Bruce R. Blazar, Elizabeth J. Shpall

Research output: Contribution to journalArticlepeer-review

37 Scopus citations

Abstract

Adoptive therapy with regulatory T cells (Tregs) to prevent graft-versus-host disease (GVHD) would benefit from a strategy to improve homing to the sites of inflammation. We hypothesized that adding fucose to human Tregs, forming the Sialyl Lewis X moiety on P-selectin glycoprotein ligand-1, would improve their trafficking pattern. The selectin pathway recruiter, α-1,3-fucosyltransferase-VI enzyme, significantly increased Treg surface fucosylation (66% vs 8%). In a xenogenic GVHD mouse model, fucosylated Tregs showed prolonged periods of in vivo persistence. When given at a lower dose compared with the untreated Tregs, the murine recipients of fucosylated Tregs maintained weight, had ameliorated clinical GVHD, and improved survival (70% vs 30%; P < .0001). These preclinical data indicate that fucosylated human Tregs is an effective strategy for prevention of GVHD and, as such, warrants consideration for future clinical trials.

Original languageEnglish (US)
Pages (from-to)1502-1506
Number of pages5
JournalBlood
Volume125
Issue number9
DOIs
StatePublished - 2015

Bibliographical note

Funding Information:
This work has been supported by the Anderson Cancer Center Start Up Funds and Lee Clark Award grants R01 HL11879, P01 CA065493, CA142106, and AI056299.

Fingerprint Dive into the research topics of 'Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo'. Together they form a unique fingerprint.

Cite this